Company Focus
Galderma
Latest Galderma News
Biotechnology
Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic dermatitis and prurigo nodularis. 18 February 2025
Dermatology News
Insights
Company Spotlight
An early commercial-stage biopharmaceutical company focused on building differentiated therapies against biologically validated targets.
Latest News & Features of interest to Galderma
Pharmaceutical
Swiss dermatology company Galderma today announced today results from its new Phase IIIb RELAX clinical trial demonstrating the rapid onset and the long-lasting duration of aesthetic efficacy, as well as high patient satisfaction and increased confidence, using a single-dose of relabotulinumtoxinA (now trade named Relfydess) to treat frown lines (glabellar lines). 31 January 2025
Biotechnology
California, USA-based biotech Allakos saw its shares plummet 78.8% to $0.26 yesterday, after it announced disappointing top-line results from its Phase I clinical trial of AK006 in chronic spontaneous urticaria (CSU). 28 January 2025
Biotechnology
Akeso has announced that its new drug application for gumokimab, an IL-17-targeting monoclonal antibody, has been accepted in China. 27 January 2025
Biotechnology
The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for patients with advanced melanoma. 22 January 2025
Biotechnology
Icelandic drug discovery and development company Arctic Therapeutics has announced the successful closing of a 26.5 million euros ($27.7 million) oversubscribed Series A financing from a broad syndicate of investors. 22 January 2025
Biotechnology
French pharma major Sanofi's participation at the JP Morgan Healthcare Conference was marked by a comprehensive overview of its position in 2024 and its strategic vision for the future. 16 January 2025
Pharmaceutical
Over the weekend, Gilead Sciences and Danish dermatology specialist LEO Pharma announced a strategic partnership, marking another move outside its traditional infectious disease area for the US antiviral giant. 13 January 2025
Biotechnology
In Beijing, a series B round for PrimeGene Science and Technology has raised over 300 million renminbi ($46 million), with money from investors including Beijing Pharmaceutical and Health Industry Investment Fund. 3 January 2025
Biosimilars
The US Food and Drug Administration (FDA) has approved Steqeyma (ustekinumab-stba), a biosimilar to Johnson & Johnson’s Stelara, from South Korea’s Celltrion. 18 December 2024
Pharmaceutical
In a review of the condition and associated drug development opportunities, GlobalData describes chronic hand eczema (CHE) as a persistent, inflammatory skin disorder characterized by redness and itching, significantly reducing quality of life (QoL). 17 December 2024
Latest In Brief for Galderma
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Latest Dermatology Ones To Watch News
The American Academy of Dermatology (AAD) meeting last week continued to provide positive news, including from US biotech Amgen and Japan’s Kyowa Kirin, with Phase III results for their rocatinlimab as a potential treatment for severe atopic dermatitis. In other news, Denmark’s Novo Nordisk released new data for its obesity hopeful CagriSema, which again failed to impress. Last week also saw US biotech 2seventy bio accept a takeover bid from Bristol Myers Squibb along with their partnered CAR-T cell therapy Abecma. Additionally, USA-based Sareum Holdings has in-licensed a cancer candidate, SRA737, from an unnamed company. 16 March 2025
21 February 2025
4 October 2024
18 September 2024
13 August 2024
Dermatology Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze